pilocarpine has been researched along with Neoplasms in 12 studies
Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
(+)-pilocarpine : The (+)-enantiomer of pilocarpine.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a crossover study comparing a mucin-based artificial saliva (Saliva Orthana) and pilocarpine hydrochloride (Salagen) in the management of xerostomia in patients with advanced cancer." | 9.08 | A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer. ( Daniels, C; Davies, AN; Pugh, R; Sharma, K, 1998) |
| "This was a crossover study comparing a mucin-based artificial saliva (Saliva Orthana) and pilocarpine hydrochloride (Salagen) in the management of xerostomia in patients with advanced cancer." | 5.08 | A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer. ( Daniels, C; Davies, AN; Pugh, R; Sharma, K, 1998) |
| "Pilocarpine is a cholinergic agent that promotes salivation." | 2.80 | Testing pilocarpine drops for dry mouth in advanced cancer using n-of-1 trials: A feasibility study. ( Agar, M; Carmont, SA; Currow, D; Good, P; Hardy, J; Mitchell, GK; Nikles, J; Schluter, PJ; Senior, H; Vora, R, 2015) |
| "D." | 2.71 | Mutans streptococci in xerostomic cancer patients after pilocarpine therapy: a pilot study. ( Chambers, MS; Gallagher, SC; Keene, HJ; Lemon, JC; Martin, CG; Martin, JW; Toth, BB, 2005) |
| "Dry mouth (xerostomia) is one of the commonest symptoms in cancer patients and can adversely affect quality of life." | 2.52 | Systematic literature review: xerostomia in advanced cancer patients. ( Adkinson, L; Daniel, S; Fleming, M; Hanchanale, S; Oxberry, SG, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanchanale, S | 1 |
| Adkinson, L | 1 |
| Daniel, S | 1 |
| Fleming, M | 1 |
| Oxberry, SG | 1 |
| Nikles, J | 1 |
| Mitchell, GK | 1 |
| Hardy, J | 1 |
| Agar, M | 1 |
| Senior, H | 1 |
| Carmont, SA | 1 |
| Schluter, PJ | 1 |
| Good, P | 1 |
| Vora, R | 1 |
| Currow, D | 1 |
| Nieuw Amerongen, AV | 1 |
| Veerman, EC | 1 |
| SCHNEYER, CA | 1 |
| PUCHKOV, NV | 1 |
| FIRSOVA, PP | 1 |
| Chambers, MS | 1 |
| Keene, HJ | 1 |
| Toth, BB | 1 |
| Lemon, JC | 1 |
| Gallagher, SC | 1 |
| Martin, CG | 1 |
| Martin, JW | 1 |
| Davies, AN | 1 |
| Daniels, C | 1 |
| Pugh, R | 1 |
| Sharma, K | 1 |
| Mercadante, S | 1 |
| Calderone, L | 1 |
| Villari, P | 1 |
| Serretta, R | 1 |
| Sapio, M | 1 |
| Casuccio, A | 1 |
| Fulfaro, F | 1 |
| Mead, GM | 1 |
| Kent, S | 1 |
| Wolff, A | 1 |
| Atkinson, JC | 1 |
| Macynski, AA | 1 |
| Fox, PC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Pilocarpine in Patients With Xerostomia[NCT02982577] | Phase 4 | 80 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for pilocarpine and Neoplasms
| Article | Year |
|---|---|
Systematic literature review: xerostomia in advanced cancer patients.
Topics: Acupuncture Therapy; Adult; Chewing Gum; Disease Progression; Humans; Neoplasms; Pilocarpine; Prospe | 2015 |
Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies.
Topics: Acupuncture Therapy; Antineoplastic Agents; Chewing Gum; Diet; Flavoring Agents; Humans; Muscarinic | 2003 |
Oral complications of cancer therapies. Pretherapy interventions to modify salivary dysfunction.
Topics: Antineoplastic Agents; Humans; Neoplasms; Pilocarpine; Radiotherapy; Salivary Glands | 1990 |
3 trials available for pilocarpine and Neoplasms
| Article | Year |
|---|---|
Testing pilocarpine drops for dry mouth in advanced cancer using n-of-1 trials: A feasibility study.
Topics: Administration, Buccal; Cell Transformation, Neoplastic; Cholinergic Agents; Cross-Over Studies; Fea | 2015 |
Mutans streptococci in xerostomic cancer patients after pilocarpine therapy: a pilot study.
Topics: Analgesics, Opioid; Colony Count, Microbial; Female; Follow-Up Studies; Humans; Longitudinal Studies | 2005 |
A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Cross-Over Studies; Female; Home Care Services; Hospitalization; Hum | 1998 |
6 other studies available for pilocarpine and Neoplasms
| Article | Year |
|---|---|
The effect of pilocarpine on tumor growth.
Topics: Animals; Neoplasms; Neoplasms, Experimental; Pilocarpine | 1957 |
[Effect of parasympathicotropic substances on the phagocyte activity of leukocytes in patients with cancer (preliminary report)].
Topics: Humans; Leukocytes; Neoplasms; Phagocytes; Phagocytosis; Pilocarpine | 1963 |
New approaches to preventing xerostomia.
Topics: Amifostine; Cytoprotection; Humans; Muscarinic Agonists; Neoplasms; Pilocarpine; Quinuclidines; Radi | 2006 |
The use of pilocarpine in opioid-induced xerostomia.
Topics: Administration, Oral; Aged; Female; Humans; Male; Middle Aged; Muscarinic Agonists; Narcotics; Neopl | 2000 |
Management of oral mucositis associated with cancer chemotherapy.
Topics: Antineoplastic Agents; Humans; Ice; Mouth Mucosa; Muscarinic Agonists; Neoplasms; Oral Hygiene; Pilo | 2002 |
Continuous drug delivery methods reflect progress in therapy for chronic diseases.
Topics: Aged; Chronic Disease; Cytarabine; Dosage Forms; Drug Implants; Glaucoma; Humans; Injections, Intrav | 1977 |